The Leishmune®'s Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis

Procedia in Vaccinology

Volumn 6, Issue , 2012, Pages 64-73

  Borja Cabrera, Gulnara P ^a,b   Santos, Flavia B ^a   Nico, Dirlei ^a   Gravino, A E ^c   Manna, Laura ^c   Palatnik, Marcos ^a   Palatnik de Sousa, Clarisa B ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b University Vale do Rio Doce   (Brazil)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Gene therapy; Immunotherapy; Nucleoside hydrolase; Visceral leishmaniasis; Zoonotic visceral leishmaniasis

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LEISHMUNE; NH36 PROTEIN; NUCLEOSIDASE; UNCLASSIFIED DRUG; VR1012NH36 VACCINE;

AMASTIGOTE; ANTIMICROBIAL ACTIVITY; ARTICLE; CANINE VISCERAL LEISHMANIASIS; CD4 CD8 RATIO; CONTROLLED STUDY; IMMUNOTHERAPY; LEISHMANIASIS; LYMPHOCYTE COUNT; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; SURVIVAL TIME; WEIGHT REDUCTION;

EID: 84860448542     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2012.04.009     Document Type: Article

References (30)

1. World Health Organization-TDR. Innovation for health. Research that makes a difference. TDR annual report | 2009. http://apps.who.int/tdr/publications/about-tdr/annual-reports/tdr-report09/pdf/tdr_annualreport09 .pdf.pp:2.
2. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies?. Am. J. Trop. Med. Hyg. 1995, 52:287-292.
3. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Review. Vaccine. 2008, 26:1709-1724.
4. Palatnik-de-Sousa C.B., Barbosa A.F., Oliveira S.M., Nico D., Bernardo R.R., Santos W.R., et al. The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine. Exp. Rev. Vaccine. 2008, 7:833-851.
5. Palatnik-de-Sousa C.B., Silva-Antunes I., Morgado A.A., Menz I., Palatnik M., Lavor C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune® in Brazilian endemic areas. Vaccine. 2009, 27:3505-3512.
6. Iovane E., Giabbai B., Muzzolini L., Matafora V., Fornili A., Minici C., et al. Structural basis for substrate specificity in group I nucleoside hydrolases. Biochemistry. 2008, 47:4418-4426.
7. Lukes J., Mauricio I.L., Schönian G., Dujardin J.C., Soteriadou K., Dedet J.P., et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl. Acad. Sci. USA. PNAS. 2007, 104:9375-9380.
8. Aguilar-Be I., Zardo R.S., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Inf. Immun. 2005, 73:812-819.
9. Souza L.O.P., Palatnik de Sousa C.B. The Nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniaisis. Proc Vaccinology. 2009, 1:120-123.
10. Gamboa-León R., Paraguai de Souza E., Borja Cabrera G.P., Santos F.N., Miyashiro L.M., Pinheiro R.O., et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani. Vaccine. 2006, 24:4863-4873.
11. Al-Wabel M.A., Tonui W.K., Cui L., Martin S.K., Titus R.G. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania. Am. J. Trop. Med. Hyg. 2007, 77:1060-1065.
12. Nico D., Claser C., Rodrigues M.M., Soares I.S., Palatnik-de-Sousa C.B. Cloning of the Nucleoside hydrolase of Leishmania donovani aiming at the development of a synthetic vaccine against visceral leishmaniasis. Proc Vaccinol. 2009, 1:115-119.
13. Nico D, Claser C, Travassos LR, Palatnik M, Soares IS, Rodrigues MM, et al. Vaccination with the Leishmune®ós Nucleoside hydrolase maps the C-terminal domain as the target of the protective immune response. Plos NTD. November, 4 (11), e866:1-13.
14. Maltezou H.C. Visceral leishmaniasis: advances in treatment. Rec. Pat. Antiinfect. Drug. Discov. 2008, 3:192-198.
15. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza W., Okada L.Y.H., Trivellato F.A.A., et al. Effective Immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine. 2004, 22:2234-2243.
16. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A.B., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine. Vaccine. 2007, 25:6176-6190.
17. Borja-Cabrera G.P., Santos F.N., Santos F.B., Trivellato F.A.A., Kawasaki J.K.A., Costa A.C., et al. Immunotherapy with the saponin enriched-Leishmune® vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine. 2010, 28:597-603.
18. Borja Cabrera G.P., da Silva V.O., da Costa R.T., Barbosa Reis A., Mayrink W., Genaro O., et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am J Trop Med 1999, 6:296-301.
19. Manna L, Reale S, Viola E, Vitale F, Manzillo VF, Michele PL et al. Leishmania DNA load and cytokine expression levels in asymptomatic naturally infected dogs. Vet. Parasitol. 142, 271-280.
20. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribáñez M.A., Alvar J., et al. Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells. Res Vet Sci. 2000, 69:249-253.
21. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribáñez M.A., Castillo J.A. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2002, 88:13-20.
22. Travi B.L., Tabares C.J., Cadena H., Ferro C., Osorio Y. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Am. J. Trop. Med. Hyg. 2001, 64:119-124.
23. Borja-Cabrera G.P., Santos F.B., Picillo E., Gravino E., Manna L., Palatnik-de-Sousa C.B. Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis. Proc. Vaccinology. 2009, 1:104-109.
24. Shuaibu M.N., Kikuchi M., Cherif M.S., Helegbe G.K., Yanagi T., Hirayama K. Selection and identification of malaria vaccine target molecule using bioinformatics and DNA vaccination. Vaccine. 2010, 28:6868-6875.
25. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases Type I and Type II of L. infantum. Vaccine. 2005, 23:3716-3725.
26. Rodríguez-Cortés A., Ojeda A., López-Fuertes L., Timón M., Atlet L., Solano-Gallego L., et al. Vaccination with plasmid DNA encoding KMP11, TRYP. LACK,and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine. 2007, 25:7962-7971.
27. Ramiro M.J., Zárate J.J., Hanke T., Rodríguez D., Rodríguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK. Vaccine. 2003, 21:2474-2484.
28. Ramos I., Alonso A., Marcen J.M., Peris A., Castillo J.A., Colmenares M., et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine. 2008, 26:333-344.
29. Carcelén J., Iniesta V., Fernández-Cotrina J., Serrano F., Parejo J.C., Corraliza I. The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection. Vaccine. 2009, 27:5964-5973.
30. Mayrink W., Botelho A.C.C., Magalhães P.A., Batista S.M., Lima A.O., Genaro O, et al. Imunoterapia, imunoquimioterapia e quimioterapia no tratamento da leishmaniose tegumentar americana. Rev. Soc. Bras. Med. Trop. 2006, 39:14-21.